Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNH
by reference. Item 3.02 Unregistered Sale of Equity Securities. The information set forth in Item 1.01 above regarding the Warrants issued to the Lender and the
by reference. The Warrants and the shares of Common Stock issuable upon exercise of the Warrants were offered and sold in reliance on the exemption from the reg
. Regulation FD Disclosure. On January 13, 2026, the Company issued a press release announcing the closing of the Loan Agreement. The press release contains sta
. Financial Statements and Exhibits. The exhibits listed in the following Exhibit Index are filed as part of this report: Exhibit No. Description 4.1 Form of Wa